Sagimet Biosciences (SGMT) Competitors

Sagimet Biosciences (NASDAQ:SGMT) and Verve Therapeutics (NASDAQ:VERV) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, community ranking, analyst recommendations, risk, profitability and earnings.

Does the MarketBeat Community prefer SGMT or VERV?

Verve Therapeutics received 5 more outperform votes than Sagimet Biosciences when rated by MarketBeat users. However, 96.55% of users gave Sagimet Biosciences an outperform vote while only 60.00% of users gave Verve Therapeutics an outperform vote.

Company	Underperform	Outperform
Sagimet Biosciences	Outperform Votes 28 96.55%	Underperform Votes 1 3.45%
Verve Therapeutics	Outperform Votes 33 60.00%	Underperform Votes 22 40.00%

Does the media favor SGMT or VERV?

In the previous week, Sagimet Biosciences had 6 more articles in the media than Verve Therapeutics. MarketBeat recorded 11 mentions for Sagimet Biosciences and 5 mentions for Verve Therapeutics. Verve Therapeutics' average media sentiment score of 0.88 beat Sagimet Biosciences' score of 0.58 indicating that Verve Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sagimet Biosciences	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Verve Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, SGMT or VERV?

Sagimet Biosciences has a beta of 2.21, meaning that its stock price is 121% more volatile than the S&P 500. Comparatively, Verve Therapeutics has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500.

Which has better earnings and valuation, SGMT or VERV?

Sagimet Biosciences has higher earnings, but lower revenue than Verve Therapeutics. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Verve Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sagimet Biosciences	$2M	132.06	-$27.88M	-$1.76	-4.89
Verve Therapeutics	$59.61M	9.45	-$200.07M	-$2.11	-3.00

Is SGMT or VERV more profitable?

Sagimet Biosciences has a net margin of 0.00% compared to Verve Therapeutics' net margin of -807.65%. Sagimet Biosciences' return on equity of -23.63% beat Verve Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sagimet Biosciences	N/A	-23.63%	-22.91%
Verve Therapeutics	-807.65%	-35.23%	-27.65%

Do analysts rate SGMT or VERV?

Sagimet Biosciences presently has a consensus price target of $23.17, indicating a potential upside of 169.07%. Verve Therapeutics has a consensus price target of $25.75, indicating a potential upside of 307.44%. Given Verve Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Verve Therapeutics is more favorable than Sagimet Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sagimet Biosciences	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Verve Therapeutics	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do insiders & institutionals have more ownership in SGMT or VERV?

87.9% of Sagimet Biosciences shares are owned by institutional investors. Comparatively, 97.1% of Verve Therapeutics shares are owned by institutional investors. 14.7% of Sagimet Biosciences shares are owned by insiders. Comparatively, 19.9% of Verve Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Sagimet Biosciences and Verve Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.